NCT00055367已完成2 期
A Phase II, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectiveness of Three Intravenous Infusions of Antegren (Natalizumab) in Adolescents With Moderately to Severely Active Crohn's Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Biogen
- 入组人数
- 30
- 试验地点
- 26
研究概览
简要总结
The purpose of this study is to determine the safety and tolerability of natalizumab in adolescents (ages 12-17) diagnosed with moderately to severely active Crohn's disease (CD). It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
Patients who complete this study may be eligible for long-term natalizumab therapy via extension protocol ELN100226-352.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients, 12-17 years of age, who have at least a six-month history of Crohn's disease and who are currently experiencing moderately to severely active Crohn's disease. Females must not be breastfeeding or pregnant, and must not become pregnant during the study.
排除标准
- 未提供
研究者
研究点 (26)
Loading locations...
相似试验
撤回
1 期
Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic OsteosarcomaPulmonary Metastatic Osteosarcoma (pOS)NCT03811886Case Comprehensive Cancer Center20
已完成
2 期
Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's DiseaseCrohn's DiseaseNCT00055536Biogen60
终止
2 期
Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving MethotrexateRheumatoid ArthritisNCT00083759Biogen299
已完成
2 期
A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)Atopic DermatitisNCT03921411Galderma R&D20
撤回
1 期
Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With AsthmaAsthmaNCT01395485Amgen